Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer

Breast

Volumn 7, Issue 6, 1998, Pages 335-339

  Kenny, F S ^a   Robertson, J F R ^a   Ellis, I O ^a   Elston, C W ^a   Blamey, R W ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

AGED; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER RECURRENCE; CANCER STATISTICS; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

EID: 0032448012     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(98)90077-7     Document Type: Article

References (24)

1. Morrow M. Breast disease in elderly women. Surg Clin North Am 1994; 74: 145-160.
2. Fentiman I S. Treatment of breast cancer in the elderly. Br J Cancer 1991; 64: 993-995.
3. Singletary S E, Shallenberger R, Guinee V F. Breast cancer in the elderly. Anns of Surg 1993; 218: 5, 667-671.
4. Hunt G E, Fry D E, Bland T I. Breast carcinoma in the elderly patient: an assessment of operative risk, morbidity and mortality. Am J Surg 1980; 140: 339-342.
5. Gaskell D J, Sangster K, Tesdale A L, Carson D, Hawkins R A. Change in the oestrogen receptor status with age - comparison of two types of assay. Br J Cancer 1992; 66: 610-613.
6. Preece P E, Wood R A, Mackie C R, Cushieri A. Tamoxifen as sole treatment of localised breast cancer in elderly women: a pilot study. BMJ 1982; 284: 871-872.
7. Bradbeer J, Kingdon J. Primary treatment of breast cancer in elderly women with tamoxifen. Clin Oncol 1983; 9: 31-34.
8. Horrobin J M, Preece P E, Dewar J A, Wood R A B, Cushieri A. Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only. Br J Surg 1991; 78: 213-217.
9. Bergman L, van Dongen J A, van Ooijen B, van Leeuwen F E. Should tamoxifen be a primary treatment choice for elderly breast cancer patients with locoregional disease? Br Cancer Res Treat 1995; 34: 77-83.
10. Gazet J-C, Ford H T, Bland J M, Markopoulos C, Coombes R C, Dixon R C. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Lancet 1988; 679-681.
11. Robertson J F R, Todd J H, Ellis I O, Elston C W, Blamey R W. Comparison of mastectomy with tamoxifen for treating elderly patients with operable breast cancer. BMJ 1988; 297: 511-514.
12. Robertson J F R, Ellis I O, Elston C W, Blamey R W. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5-year follow-up. Eur J Cancer 1992; 28A: 908-910.
13. Haywood J L, Carbone P P, Heuson J C, Kumaoka S, Rubens R. Assessment of response to therapy in advanced breast cancer: a project of the programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977; 39: 1289-1294.
14. Elston C W, Ellis I O. Pathological prognostic factors in breast cancer, experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
15. Gazet J-C, Ford H T, Coombes R C, Bland J M, Sutcliffe R, Quilliam J, Lowndes S. Prospective randomised trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Onc 1994; 20: 207-214.
16. Bates T, Riley D L, Houghton J, Fallowfield L, Baum M. Breast cancer in elderly women: a Cancer Research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. Br J Surg 1991; 78: 591-594.
17. Latteier J, Bates T, Riley D L, Houghton J, Baum M. The addition of surgery to tamoxifen as primary treatment of early breast cancer in women over 70, a multi-centre trial (abstract). The Breast 1997; 6: 244.
18. EBCTCG (Early Breast Cancer Trialists' Collaborative Group): Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992; 339: 1-15, 71-85.
19. Willsher P C, Robertson J F R, Jackson L, Al-Hilaly M, Blamey R W. Investigation of primary tamoxifen therapy for elderly patients with operable breast cancer. The Breast 1997; 6: 150-154.
20. Keen J C, Dixon J M, Miller E P et al. The expression of Ki-Sl and bcl-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer. Br Cancer Res Treat 1997; 44: 123-133.
21. Soubeyran I, Quenel N, Coindre J-M et al. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Br J Cancer 1996; 74: 1120-1125.
22. Wilson Y G, Rhodes M, Ibrahim N B N, Padfield C J H, Cawthorn S J. Immunocytochemical staining of pS2 protein in fine-needle aspirate from breast cancer is an accurate guide to response to tamoxifen in patients aged over 70 years. Br J Surg 1994; 81: 1155-1158.
23. Williams M R, Hinton C P, Todd J H, Morgan D A L, Elston C W, Blamey R W. The prediction of local or regional recurrence after simple mastectomy for operable breast cancer. Br J Surg 1985; 72: 721-723.
24. Fisher B, Redmond C, Fisher E R et al. Ten year results of a randomised clinical trial comparing radical mastectomy and total mastectomy with or without radiation. New Engl J Med 1985; 312: 674-681.